Table 2.
Baseline characteristics of the 2009–2010 LFAC cohort overall, stratified by attendance
| Overall | Attendance at V1 | Attendance at V2 | |||
|---|---|---|---|---|---|
|
| |||||
| Yes | No | Yes | No& | ||
| N | 286 | 214 | 72 | 144 | 70 |
| Age (years) | 18.6±4.5 | 18.3±4.4ǂ | 19.4±4.7 | 17.5±4.7* | 19.9±4.3 |
| Male %(n) | 46.5 (133) | 44.9 (96) | 51.4 (37) | 35.4 (51)* | 67.1 (47) |
| Diagnosis Age (years) | 15.1±4.8 | 15.0±4.7 | 15.7±5.4 | 14.2±4.7* | 15.8±5.3 |
| Seen in 2009 %(n) | 46.2 (132) | 44.9 (96) | 50.0 (36) | 69.4 (100)* | 45.7 (32) |
| Duration (years) | 3.4±3.1 | 3.3±2.9 | 3.5±3.8 | 3.3±2.8 | 4.0±3.4 |
| HbA1c (%) | 11.2±2.7 | 11.3±2.7 | 11.0±2.6 | 11.4±2.5 | 11.2±2.6 |
| HbA1c (mmol/mol) | 99±30 | 100±30 | 97±28 | 101±27 | 99±28 |
| HbA1c >14% %(n) | 30.8 (88) | 32.7 (70) | 25.0 (18) | 30.6 (44) | 27.1 (19) |
| HbA1c <8% %(n) | 15.7 (45) | 16.4 (35) | 13.9 (10) | 11.1 (16) | 18.6 (13) |
| Glucose Monitor / wk | 1.1±3.4 | 1.0±3.2 | 1.4±4.2 | 1.7±4.4ǂ | 0.66±2.1 |
| Insulin units/kg | 0.73±0.36 | 0.75±0.39ǂ | 0.66±0.28 | 0.75±0.41 | 0.74±0.36 |
| Height (cm) | 154.2±14.7 | 153.6±14.6 | 155.8±15.1 | 151.6±14.5 | 156.9±17.3 |
| Height Z-score$ | −1.6±1.8 | −1.8±1.8ǂ | −1.0±1.7 | −1.7±1.8 | −1.3±1.7 |
| Short Stature %(n)$ | 48.2 (42) | 52.3 (34) | 36.4 (8) | 46.2 (24) | 42.9 (6) |
| Weight (kg) | 48.1±12.7 | 47.6±13.0 | 49.3±11.9 | 46.7±14.0 | 50.5±12.2 |
| BMI (kg/m2) | 20.2±4.0 | 20.1±3.9 | 20.2±4.3 | 20.2±4.1 | 20.5±4.8 |
| Underweight %(n) | 18.6 (53) | 19.6 (42) | 15.5 (11) | 16.7 (24) | 21.4 (15) |
| Healthy Weight %(n) | 69.5 (198) | 66.8 (143) | 77.5 (55) | 66.0 (95) | 34.0 (49) |
| Overweight %(n) | 5.0 (14) | 5.1 (11) | 4.2 (3) | 6.9 (10) | 1.4 (2) |
| Obese %(n) | 2.1 (6) | 2.3 (5) | 1.4 (1) | 2.8 (4) | 1.4 (2) |
| BMI Z-score$ | −0.7±1.4 | −0.7±1.4 | −0.7±1.1 | −0.6±1.6 | −0.6±0.8 |
| Systolic BP (mmHg) | 112±15 | 112±14 | 114±18 | 111±16ǂ | 115±15 |
| Systolic BP Z-score$ | −0.1±1.0 | −0.04±1.1 | −0.4±0.7 | −0.2±1.0 | −0.1±0.8 |
| Diastolic BP (mmHg) | 72±11 | 72±11.0 | 72.7±11 | 72±11 | 74±10 |
| Diastolic BP Z-score$ | 0.5±0.7 | 0.5±0.7 | 0.4±0.6 | 0.5±0.7 | 0.4±0.6 |
| Hypertension %(n)¥ | 31.8 (91) | 30.8 (66) | 34.7 (25) | 28.4 (41) | 38.6 (27) |
| Microalbuminuria %(n) | 21.0 (31)a | 20.5 (23)c | 21.6 (8)e | 20.4 (21)g | 21.2 (7)i |
| Nephropathy %(n) | 4.7 (7)a | 6.2 (7)c | 0.0 (0)e | 3.9 (4)g | 3.0 (1)i |
| Neuropathy %(n) | 2.1 (5)b | 2.3 (4)d | 1.6 (1)f | 1.8 (2)h | 5.1 (3)j |
|
|
|||||
| at V1 (one-year) and V2 (two- year) visits. | |||||
&
Includes only those who were eligible for a two-year follow –up
$
Indicates variable calculated for participants <18 years only
¥
Rates were calculated by adding those who were <18 years and ≥95th percentile with those who were ≥18 years and met the definition of hypertension based on BP
*
Indicates significance at α < 0.05
ǂ
Indicates borderline significance at α <0.1
a
=118 tested;
b
=180 tested;
c
=112 tested;
d
=174 tested;
e
=37 tested;
f
=62 tested,
g
=103 tested,
h
=5 tested,
I
=33 tested,
j
=59 tested